Literature DB >> 14564014

Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.

Xianghui Yu1, Yunkai Yu, Bindong Liu, Kun Luo, Wei Kong, Panyong Mao, Xiao-Fang Yu.   

Abstract

Human immunodeficiency virus-1 (HIV-1) Vif is essential for viral evasion of host antiviral factor CEM15/APOBEC3G. We report that Vif interacts with cellular proteins Cul5, elongins B and C, and Rbx1 to form an Skp1-cullin-F-box (SCF)-like complex. The ability of Vif to suppress antiviral activity of APOBEC3G was specifically dependent on Cul5-SCF function, allowing Vif to interact with APOBEC3G and induce its ubiquitination and degradation. A Vif mutant that interacted with APOBEC3G but not with Cul5-SCF was functionally inactive. The Cul5-SCF was also required for Vif function in distantly related simian immunodeficiency virus mac. These results indicate that the conserved Cul5-SCF pathway used by Vif is a potential target for antiviral development.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564014     DOI: 10.1126/science.1089591

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  637 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification.

Authors:  Rahul M Kohli; Robert W Maul; Amy F Guminski; Rhonda L McClure; Kiran S Gajula; Huseyin Saribasak; Moira A McMahon; Robert F Siliciano; Patricia J Gearhart; James T Stivers
Journal:  J Biol Chem       Date:  2010-10-06       Impact factor: 5.157

Review 3.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

4.  Analysis of human APOBEC3H haplotypes and anti-human immunodeficiency virus type 1 activity.

Authors:  Xiaojun Wang; Aierken Abudu; Sungmo Son; Ying Dang; Patrick J Venta; Yong-Hui Zheng
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

5.  HIV-1 Vif interaction with APOBEC3 deaminases and its characterization by a new sensitive assay.

Authors:  Iris Cadima-Couto; Nuno Saraiva; Ana Catarina C Santos; Joao Goncalves
Journal:  J Neuroimmune Pharmacol       Date:  2011-01-29       Impact factor: 4.147

6.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

7.  Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.

Authors:  Yunkai Yu; Zuoxiang Xiao; Elana S Ehrlich; Xianghui Yu; Xiao-Fang Yu
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

8.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates.

Authors:  Nadia J Kershaw; Artem Laktyushin; Nicos A Nicola; Jeffrey J Babon
Journal:  Growth Factors       Date:  2014-01-20       Impact factor: 2.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.